Last reviewed · How we verify

Glenmark Pharmaceuticals Ltd. India — Portfolio Competitive Intelligence Brief

Glenmark Pharmaceuticals Ltd. India pipeline: 2 marketed, 0 filed, 5 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 5 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Diclofenac Sodium gel, 1% Diclofenac Sodium gel, 1% marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Rheumatology
Voltaren® Gel Voltaren® Gel marketed Topical NSAID COX-1 and COX-2 enzymes Pain Management / Rheumatology
DYMISTA nasal spray DYMISTA nasal spray phase 3 Antihistamine/Intranasal corticosteroid combination H1 receptor (azelastine); Glucocorticoid receptor (fluticasone propionate) Allergy/Immunology
Placebo of Tacrolimus Ointment Placebo of Tacrolimus Ointment phase 3 immunosuppressant calcineurin Immunology
Protopic® ointment, 0.1% Protopic® ointment, 0.1% phase 3 calcineurin inhibitor calcineurin Dermatology
Elidel® (pimecrolimus) Cream Elidel® (pimecrolimus) Cream phase 3 Calcineurin inhibitor (topical immunosuppressant) Calcineurin (via macrophilin-12 binding) Dermatology/Immunology
Placebo of Pimecrolimus Cream, 1% Placebo of Pimecrolimus Cream, 1% phase 3 Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Sanofi · 2 shared drug classes
  3. Amneal Pharmaceuticals, LLC · 1 shared drug class
  4. Assaf-Harofeh Medical Center · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
  7. Bausch & Lomb Incorporated · 1 shared drug class
  8. Amzell · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Glenmark Pharmaceuticals Ltd. India:

Cite this brief

Drug Landscape (2026). Glenmark Pharmaceuticals Ltd. India — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/glenmark-pharmaceuticals-ltd-india. Accessed 2026-05-16.

Related